| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.43B | +57.8% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥-0.05B | — |
| Net income | ¥-0.04B | -2189.4% |
| Gross margin | 24.6% | Net margin -9.3% |
| Revenue Q/Q | -33.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.32B | 75.4% |
| R&D | ¥0.03B | 5.9% |
| SG&A | ¥0.15B | 34.4% |
| Tax & other | ¥-0.01B | -1.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
富瑞特装 ・ 拓尔思 ・ 永利股份 ・ 银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies